Product Description
Utilizing wireless wearable sensors, MC10 BiostampRC, to capture quantitative biometric and movement-based data. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04219670)
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Canada | Chile | Colombia | Dominican Republic | India | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Emyria
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Emerald-NRAD | N/A |
Not yet recruiting |
Cognitive Dysfunction|Alzheimer Disease |
2025-04-30 |
|
OPAL | N/A |
Completed |
Parkinson's Disease |
2024-05-07 |
|
EMERALD | N/A |
Completed |
Gastrointestinal Cancer|Gastroesophageal Reflux|Esophageal Cancer|Esophagitis|Barrett Esophagus|Adenocarcinoma |
2024-04-24 |
|
SENS-101-RSRT | N/A |
Completed |
Rett Syndrome |
2023-03-01 |